ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Heart/lung transplantation"

  • 2021 American Transplant Congress

    Quilty Lesions are Associated with a Tolerance Profile in Heart Allografts Biopsies

    J. Torrealba, S. Moore, S. Sathirareuangchai, L. De Las Casas, Q. Cai

    Pathology, UTSW Medical Ctr, Dallas, TX

    *Purpose: Previously, in 42 cardiac allograft biopsies, we demonstrated that the presence of Foxp3+ innate and TGF- β + adaptive regulatory lymphocytes in Quilty lesions…
  • 2021 American Transplant Congress

    Use of Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Scoping Review

    A. G. Anderson, M. Eubank, K. Murray

    University of Missouri, Columbia, MO

    *Purpose: Immune checkpoint inhibitors (ICI) are an emerging treatment for numerous advanced diseases, but their safety and efficacy in immunosuppressed transplant patients is not known.…
  • 2021 American Transplant Congress

    Acute Kidney Injury Requiring Dialysis in Heart Transplant Recipients is a Risk Factor for Graft Failure and Overall Mortality

    M. A. Merzkani, H. Murad, A. Pottebaum, A. Java, A. Malone, J. Schilling, A. Itoh, R. Delos Santos, T. Alhamad

    Transplant, Washington University, Saint Louis, MO

    *Purpose: Acute Kidney Injury (AKI) is a frequent complication of heart transplantation. However, with recent allocation changes, we have increasingly complex patients with a higher…
  • 2021 American Transplant Congress

    Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19

    W. Cochran1, R. Avery2, D. Brennan2, N. Lawrence2, A. Brown2, S. Sullivan2, B. Adams2, M. McCarthy2, S. Ellis2, F. Naqvi2, E. Kraus2, N. Alachkar2, S. Alasfar2, F. Al Ammary2, J. Horn2, L. Hartman2, L. Fessler2, S. Purekal2, Z. Siddiqui2, D. Carter2, J. Ficke2, M. Kantsiper2, L. Boyer2, I. Gupta2, A. Gurakar2, D. Ostrander2, J. Langlee2, S. Shoham2, K. Marr2, P. Shah2

    1Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, 2Johns Hopkins, Baltimore, MD

    *Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
  • 2021 American Transplant Congress

    Early Outcome of Heart-Kidney Transplantation in the Current Heart Allocation System in the United States

    S. Rao1, A. Doyle1, D. Brennan2, S. Constantinescu3

    1University of Virginia, Charlottesville, VA, 2Johns Hopkins Medical Institute, Baltimore, MD, 3Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    *Purpose: In the United States, heart allograft allocation is a primary determinant for heart-kidney transplantation (HKT). We analyzed the OPTN dataset and compared the outcomes…
  • 2021 American Transplant Congress

    The Role of Notch2 in Antibody-mediated Alloimmune Response

    R. Benedetti Gassen1, N. Murakami2, T. J Borges1, A. Al Jurdi1, A. Alessandrini1, L. V Riella1

    1Center of Transplantation Science, Massachusetts General Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

    *Purpose: Antibody mediated rejection is the leading cause of chronic allograft rejection. Developing a novel therapeutic target to inhibit chronic rejection is an urgent need…
  • 2021 American Transplant Congress

    P40 Homodimers Induce Il-15 to Promote Endogenous Donor-reactive Memory Cd8 T Cell Activation within High-risk Cardiac Allografts

    H. Tsuda, A. Valujskikh, R. Fairchild

    Inflammation and Immunity, Cleveland Clinic, Cleveland, OH

    *Purpose: Longer cold ischemic storage (CIS) time prior to transplant results in increased proliferation of endogenous donor-reactive memory CD8 T cells within complete MHC-mismatched cardiac…
  • 2021 American Transplant Congress

    Life-supporting Multi-gene Cardiac Xenografts From Swine Demonstrate Survival >8 Months and Preclinical Efficacy for Human Clinical Trials

    C. Goerlich1, B. Griffith1, A. Singh1, T. Zhang1, I. Tatarov1, B. Lewis1, F. Sentz1, A. Hershfeld1, P. Odonkor1, B. Williams1, E. Strauss1, A. Tabatabai2, A. Bhutta3, D. Ayares4, D. Kaczorowski1, M. Mohiuddin1

    1Surgery, University of Maryland School of Medicine, Baltimore, MD, 2Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, 3Pediatrics, Pediatric Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, 4Revivicor, Inc., Blacksburg, VA

    *Purpose: Cardiac xenotransplantation has been proposed to bridge the gap in organ shortage for those in end-stage heart failure without the opportunity to receive a…
  • 2021 American Transplant Congress

    Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation

    M. Hudson, A. Webb, A. Logan, A. Silverman, A. Brueckner

    Pharmacy, Tampa General Hospital, Tampa, FL

    *Purpose: The purpose of this study was to assess the clinical impact of utilizing hepatitis C virus (HCV) nucleic acid testing (NAT)+ donors in HCV…
  • 2021 American Transplant Congress

    Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors

    B. Aqel1, H. Khamash2, A. Moss3, D. E. Steidley4, R. C. Dickson1

    1Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, 2Nephrology and Hypertension, Mayo Clinic, Phoenix, AZ, 3Transplant Surgery, Mayo Clinic, Phoenix, AZ, 4Cardiology, Mayo Clinic, Phoenix, AZ

    *Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2026 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences